Analysis of the efficacy of trastuzumab combined with vinorelbine therapy in the treatment of human epithelial growth factor recepeor-2 positive advanced breast cancer
10.3760/cma.j.issn.1673-4904.2017.04.017
- VernacularTitle:曲妥珠单抗联合长春瑞滨治疗人表皮生长因子受体2阳性晚乳腺癌疗效分析
- Author:
Shengyu SHI
;
Peifen FU
;
Jianhua CHEN
;
Yan ZHAO
- Keywords:
Breast neoplasms;
Trastuzumab;
Vinorelbine;
Capecitabine;
Treatment outcome
- From:
Chinese Journal of Postgraduates of Medicine
2017;40(4):353-357
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of trastuzumab combined with vinorelbine therapy in the treatment of advanced breast cancer with human epithelial growth factor receptor-2 (HER-2) positive.Methods From April 2010 to April 2013,91 advanced breast cancer patients who failed in the paclitaxel therapy received trastuzumab plus vinorelbine (45 cases,vinorelbine group) or capecitabine (46 cases,capecitabine group).The treatment efficacy,toxic effects and 3-year survival rate in two groups were compared.Results The clinical benefit rate in two groups had no significant difference (P ＞ 0.05),but objective response rates in vinorelbine group was higher than that in capecitabine group:44.44％(20/45) vs.23.91％(11/46),and there was significant difference (P =0.039).The toxic effects in two groups had no significant difference (P ＞ 0.05).The 3-year survival rate in two groups had no significant difference (P =0.252).Conclusions In the treatment of HER-2 positive advanced breast cancer,trastuzumab plus vinorelbine or capecitabine shows no significant differences in adverse reaction or in 3-year survival rate.However,trastuzumab plus vinorelbine shows better objective response rate compared with trastuzumab plus capecitabine.
